PTEN protein loss in prostate cancer triggers extensive stromal remodeling through enhanced transforming growth factor beta (TGF-β) signaling and senescent cell paracrine communication. Researchers combined immunohistochemistry with transcriptional analysis across human and murine prostate tumors, revealing that PTEN-deficient cancer cells activate a secretome program that reprograms surrounding stromal tissue. This stromal response appears mediated by senescent cancer cells releasing factors that drive tissue remodeling beyond the well-known PI3K-AKT-mTOR pathway effects within cancer cells themselves. The discovery fundamentally reframes PTEN loss as not just a cancer cell proliferation driver, but as an orchestrator of tumor microenvironment transformation. This finding bridges cancer biology with aging research, as senescent cell accumulation and their inflammatory secretome are increasingly recognized as drivers of age-related diseases. The ability to substratify PTEN-loss tumors based on their stromal senescence signatures could improve prognostic accuracy, potentially identifying which patients harbor more aggressive disease despite similar genetic profiles. However, translating these transcriptional signatures into clinical practice will require validation in larger cohorts and development of practical biomarker assays beyond complex genomic profiling.